To screen and identify the potential targets and pathways of Danthron against breast cancer based on network pharmacology, and to verify its mechanisms through transcriptomic analysis and in vitro and in vivo experiments.

Multiple databases were integrated to screen the common targets of Danthron and breast cancer for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. CCK-8 and colony formation assays were used to evaluate cell proliferation. Transcriptome sequencing and quantitative real-time polymerase chain reaction (qPCR) were performed to analyze the expression of Cxcl10, Isg15, IL-6, Nlrp3, and Bax and other related genes. A mouse 4T1 xenograft model was established to observe and assess the antitumor effect of Danthron.

A total of 84 intersecting targets were obtained, mainly enriched in the Apoptosis, p53, PI3K-Akt, NOD-like receptor, and Cytokine signaling pathways. Danthron significantly inhibited breast cancer cell proliferation (IC₅₀=30.05 μmol·L^‐1), upregulated interferon-stimulated genes (Irf7, Isg15, Ifit1) and chemokines (Cxcl10, IL‐6), and upregulated the expression of Nlrp3 and Bax. In vivo, Danthron significantly suppressed 4T1 xenograft growth and reduced Ki-67 expression.

Danthron exerts antitumor activity against breast cancer by activating interferon responses and inflammation-apoptosis-related pathways, providing a theoretical basis for its development as a potential natural anticancer agent.

Baricitinib, a JAK1/JAK2 inhibitor, is already used to treat rheumatoid arthritis and other immune diseases. Clinical trials have demonstrated its effectiveness, but long-term use may lead to adverse drug reactions (ADRs) such as infections, thrombosis, and liver dysfunction. Real-world safety studies of baricitinib are limited. This study aims to evaluate the safety of baricitinib using the FDA Adverse Event Reporting System (FAERS) database.

This study adopted baricitinib-related report data from the FAERS database for the period from the third quarter of 2017 to the fourth quarter of 2023. Data cleaning and screening were conducted using the OpenVigil 2.1 platform, excluding duplicate and irrelevant reports. Signal detection was performed using four statistical methods, including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)(hereinafter referred to as ROR and PRR), to analyze the potential risks of baricitinib-related ADRs. Descriptive statistical analyses were also conducted.

From 2017 to 2023, a total of 47 776 724 adverse event reports related to baricitinib were received, and after data cleaning, 9 592 793 reports were included in the final analysis. Among these reports, female patients accounted for 61.4%, and most reports originated from the United States (45.4%). The main adverse reactions included pulmonary embolism, deep vein thrombosis, herpes zoster, and mitral valve perforation, with some signals (e.g., interstitial lung disease, ischemic stroke) not mentioned in the drug package insert. Baricitinib-related ADRs primarily involved infections, respiratory, nervous, and cardiovascular systems.

Through the latest database, this study reflects the real-world safety data of baricitinib over a longer time period. The research found that the main adverse reactions of baricitinib include infections, pulmonary embolism, and herpes zoster, and for the first time identified previously unreported risk signals, such as interstitial pneumonia and atrial fibrillation. This study provides updated evidence for both the academic community and clinical practice, offering guidance for patient management in future clinical applications. In clinical practice, special attention should be paid to the safety of elderly patients and high-risk groups to ensure rational use.

To first systematically mine and characterize the real-world drug safety signals of the EZH2 inhibitor tazemetostat using the FDA Adverse Event Reporting System (FAERS) database, to provide evidence-based support for clinical risk management.

A dual-algorithm validation framework (Reporting Odds Ratio, ROR + Proportional Reporting Ratio, PRR) was applied to analyze 1 225 reports listing tazemetostat as the primary suspected drug submitted between Q1 2020 and Q1 2025. False positives were controlled using χ² > 4. After excluding Preferred Terms (PTs) related to the drug's indication and non‐drug-related System Organ Classes (SOCs), 94 valid signals (involving 1 690 reports) were ultimately identified.

(1) Twenty- four signals (25.5% of total signals) not listed in the current drug package insert were detected. Strong signals included dysgeusia (ROR = 17.39, 95%CI = 13.00-23.27), parosmia (ROR = 10.91, 95%CI = 4.53-26.25), and decreased red blood cell count (ROR=6.94, 95%CI = 4.11-11.73). (2) The most frequently reported signals were fatigue (12.8%), nausea (9.3%), and diarrhea (7.6%). (3) Multisystem toxicity was observed, primarily involving the gastrointestinal system (33.08%), general reactions (25.21%), and nervous system (9.23%).

This is the first comprehensive pharmacovigilance study of tazemetostat reveals its potential to induce multisystem toxicity, mediated through neurosensory pathways and bone marrow hematopoietic homeostasis. The identification of unlisted signals challenges the traditional view that EZH2 inhibitor toxicity is confined to proliferative tissues. These findings provide crucial real-world evidence supporting the theory of systemic toxicity for epigenetic drugs and hold significant value for optimizing clinical drug monitoring strategies during tazemetostat therapy.

To systematically investigate the folk cognition, application methods, and resource situation of Artemisia verlotiorum Lamotte in the Luofu Mountain area, Guangdong Province.

A combination of literature research and ethnobotanical investigation was adopted.

Artemisia verlotiorum Lamotte has extremely high folk cognition locally (96.00% among residents, 100.00% among medical staff). Its applications span multiple areas of folk custom and healthcare: residents commonly use it to make making Ai cakes (88.00%), foot baths (52.00%), and postpartum bathing (48.00%), reflecting profound dietary and health-preserving traditions. Medical staff widely apply it to treat gynecological conditions (e.g., dysmenorrhea 58.93%, uterine cold 41.07%), internal diseases (stomach cold 35.71%), and rheumatic diseases (32.14%), reflecting characteristics of syndrome differentiation and treatment based on traditional Chinese medicine theory. The survey also found a high prevalence of Artemisia verlotiorum Lamotte cultivation (88.00%), including large-scale planting. Through the survey of medical workers, it was found that although this traditional knowledge faces the challenge of inheritor faultage (98.18% of them lack inheritors), most medical workers (72.73%) still have a strong willingness to organize and preserve this experiential knowledge.

Artemisia verlotiorum Lamotte integrates folk identity with practical medicinal utility. Future efforts should focus on its resource protection, sustainable utilization, and the effective inheritance of related traditional medical knowledge.

To investigate the off-label use of pregabalin in the outpatient department of a hospital, analyze the types, reasons, and potential risks of such usage, and provide reference for improving the safety and rationality of its use.

A total of 2 183 outpatient prescriptions containing pregabalin issued between May 2023 and April 2024 were selected.Patient basic information, demographics, clinical diagnoses, and concomitant medications were recorded.

Among the 2 183 prescriptions, 421 (19.29%) involved off-label use.The primary categories included off-label indications (94.06%), off-label patient populations (1.66%), and concomitant medications (4.28%). Additionally, 281 prescriptions (12.87%) were deemed irrational, mainly due to inappropriate indications (26 cases) and altered dosing frequency (255 cases).

Off-label use of pregabalin is prevalent in the dermatology outpatient department of the hospital. However, significant irrational prescribing practices exist.The hospital should refine and enforce relevant systems, enhance physician training and patient education, and conduct in‐depth specialized prescription reviews and risk assessments to ensure medication safety and rational use.

To evaluate the efficacy of sintilimab plus bevacizumab combined with hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) and explore their effects of this combined regimen on macrophage function and phenotype.

Patients with advanced HCC admitted to a hospital from September 2022 to May 2024 were prospectively selected and randomly divided into a control group and an observation group, with 50 cases in each group.The control group received HAIC alone, while the observation group received HAIC combined with sintilimab and bevacizumab. The differences in short-term clinical efficacy, functional indices, and adverse reactions between the two groups were compared.A 6-month follow-up was conducted on patients in both groups after the end of treatment to evaluate long-term efficacy.

After treatment, the observation group exhibited higher disease control rate (DCR), objective response rate (ORR), median progression-free survival (PFS), mean overall survival (OS), macrophage count, proportion of anti-tumor phenotype (M1 type) macrophages, and counts of CD₃⁺, CD₄⁺, and CD₈⁺ T lymphocytes compared to the control group (all P < 0.05). The observation group also showed lower levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), proportion of immunosuppressive phenotype (M2 type) macrophages, and interleukin-6 (all P < 0.05). The incidence of adverse reactions was lower in the observation group, though the difference was not statistically significant (all P > 0.05).

The combination of sintilimab and bevacizumab with HAIC in the treatment of advanced hepatocellular carcinoma can effectively improve short-term and long-term clinical efficacy, improve liver function, regulate macrophage function and phenotype, and enhance the cellular immune function of patients.

To investigate the initial and subsequent treatment strategies for NSCLC with concurrent EGFR mutations and PD-L1 expression, and to summarize the diagnostic and therapeutic approaches so as to provide references for treatment decisions for such patients.

The treatment plan of a patient with NSCLC harboring EGFR mutations and PD-L1 expression was analyzed.

The patient was diagnosed with adenocarcinoma of the right lung with EGFR mutations and expression of PD-L1.The initial treatment plan was osimertinib combined with pemetrexed and carboplatin, and the patient ultimately achieved a progression-free survival (PFS) of 39 months from September 2020 to December 2023. On December 27, 2023, re-examination revealed chronic disease progression, and the regimen was adjusted to osimertinib combined with bevacizumab. On March 12, 2024, the patient experienced disease progression, with no significant changes in genetic testing. Chemotherapy was considered for reinitiation, and we selected the treatment regimen of "pemetrexed + carboplatin + sintilimab + anlotinib". After one cycle, a follow-up CT scan demonstrated a partial response (PR), and PR was maintained after the second cycle.

This study reports a case of advanced NSCLC with EGFR mutations and PD-L1 expression. In the treatment of this patient, an individualized diagnosis and treatment plan was formulated through literature review and relevant genetic testing. By combining immunotherapy, chemotherapy and anti-angiogenic drugs, the patient's disease was effectiveI resistance are complex and vary based on individual patient differences and tumor locations. After disease progression, re-genetic testing may clarify the resistance mechanisms and guide clinical treatment to achieve better efficacy and precision treatment.

To optimize the discharge medication dispensing process, shorten patients' waiting time for medications, and improve patients'medical service experience.

The discharge medication dispensing process was comprehensively reconstructed by implementing measures such as introducing a medication pickup medication pickup check-in system, issuing doctor's orders for "pre -discharge medications" one day in advance, and prescribing doctor's orders for "same -day discharge medications" during off-peak hours. The patients' queuing time for medications and satisfaction with pharmaceutical care were compared before and after the optimization.

After the process reconstruction and optimization, the average time from payment to medication pickup at the window for patients decreased significantly. The average time from check-in to medication pickup was only 5.5 min, patients'satisfaction scores were significantly improved.

Optimization based on the traditional discharge medication dispensing process has significantly shortened the queuing time for patients picking up discharge medications, improved their medical experience, and enhanced patients'satisfaction with pharmaceutical care.

To clarify the effects of betulinic acid on autophagic flux and apoptosis in RPMI-8226 multiple myeloma cells, and to explore the underlying mechanisms.

The apoptosis rate and morphological changes were detected by TUNEL and Hoechst 33258 staining methods; the activities of Caspase-3 and Caspase-8 were measured using the Caspase activity assay kits. The expression of various indicator proteins in cells was detected by Western blotting.

Betulinic acid induced apoptosis and morphological changes in RPMI-8226 cells. Z-VAD-FMK inhibited the pro-apoptotic effect of betulinic acid, while Z-DEVD-FMK further enhanced the pro-apoptotic effect of betulinic acid. Additionally, betulinic acid increased the accumulation of autophagy-related proteins LC3B and P62, promote the activation and protein expression of Caspase-8, and subsequently increase the release of AIF. Z-VAD-FMK antagonized the effects of betulinic acid on LC3B, P62, Caspase-8 and AIF, whereas Z-DEVD-FMK synergized with betulinic acid to enhance its effects on LC3B, P62, Caspase-8 and AIF.

Betulinic acid can directly activate Caspase-3 in RPMI-8226 cells. After acting on RPMI-8226 cells, it can also activate Caspase-8 by blocking autophagic flux, increase mitochondrial membrane permeability, and thereby enhance the release of AIF, thereby mediating an apoptotic process independent of Caspase-3 activation.